Annals of Surgical Oncology

, Volume 9, Issue 10, pp 961–967 | Cite as

Prognostic value of baseline and serial carcinoembryonic antigen and carbohydrate antigen 19.9 measurements in patients with pseudomyxoma peritonei treated with cytoreduction and hyperthermic intraperitoneal chemotherapy

  • S. van Ruth
  • A. A. M. Hart
  • J. M. G. Bonfrer
  • V. J. Verwaal
  • F. A. N. Zoetmulder
Original Articles



Tumor markers are useful for diagnosis and follow-up. We studied the prognostic value of baseline and serial carcinembryonic antigen (CEA) and carbohydrate antigen 19.9 (CA 19.9) measurements in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).


Sixty-three patients with pseudomyxoma peritonei were treated with cytoreductive surgery and HIPEC. The tumor markers CEA and CA19.9 were collected before therapy and at 3-month intervals during follow-up.


Preoperative CEA and CA19.9 levels were increased in, respectively, 75% and 58% of the patients. Baseline tumor marker values were related to the extent of tumor. Immediately after HIPEC, both tumor markers decreased markedly (P<.0001). CA19.9 was shown to be a more useful tumor marker than CEA for follow-up. During follow-up, a high absolute CA19.9 level (P=.0005) was predictive for imminent recurrence. Patients who never attained a normal CA19.9 level showed a higher recurrence rate at 1 year (53%; SE, 15%), in comparison to patients with did so (6%; SE 4%). The median lead time of increased CA19.9 to recurrence was 9 months.


The measurement of the tumor marker CA19.9 is useful in evaluating therapy in patients with pseudomyxoma peritonei treated with cytoreductive surgery and HIPEC. CA19.9 is a prognostic factor for predicting recurrent disease.

Key Words

CEA antigen CA19.9 antigen Prognostic value Pseudomyxoma peritonei Recurrence HIPEC 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Sugarbaker PH, Ronnett BM, Archer A, et al. Pseudomyxoma peritonei syndrome.Adv Surg 1996;30:233–80.PubMedGoogle Scholar
  2. 2.
    Hsieh SY, Chiu CT, Sheen IS, Lin DY, Wu CS, et al. A clinical study on pseudomyxoma peritonei.J Gastroenterol Hepatol 1995;10:86–91.PubMedGoogle Scholar
  3. 3.
    Landen S, Bertrand C, Maddern GJ, et al. Appendiceal mucoceles and pseudomyxoma peritonei.Surg Gynecol Obstet 1992;175:401–4.PubMedGoogle Scholar
  4. 4.
    Kuo CM, Kuo CH, Changchien CS, Chiu KW, Hsu TT. Pseudomyxoma peritonei with high serum CA19-9: report of three cases.Changgeng Yi Xue Za Zhi 1999;22:94–9.PubMedGoogle Scholar
  5. 5.
    Maekawa Y, Nakamura K, Nogami R. A case of dermatomyositis associated with pseudomyxoma peritonei originating from mucinous adenocarcinoma of the appendix.J Dermatol 1992;19:420–3.PubMedGoogle Scholar
  6. 6.
    Witkamp AJ, de Bree E, Kaag MM, van Slooten GW, van Coevorden F, Zoetmulder FA. Extensive surgical cytoreduction and intraoperative hyperthermic intraperitoneal chemotherapy in patients with pseudomyxoma peritonei.Br J Surg 2001;88:458–63.PubMedCrossRefGoogle Scholar
  7. 7.
    Molina R, Bonfrer J, Banfi G, et al. External evaluation of LIAISON tumour marker assays on the fully automated chemiluminescent LIAISON immunoassay analyser.Clin Lab 2000;46:169–79.PubMedGoogle Scholar
  8. 8.
    Simon R, Makuch RW. A non-parametric graphical representation of the relationship between survival and the occurrence of an event: application to responder versus non-responder bias.Stat Med 1984;3:35–44.PubMedGoogle Scholar
  9. 9.
    Forones NM, Tanaka M. CEA and CA 19-9 as prognostic indexes in colorectal cancer.Hepatogastroenterology 1999;46:905–8.PubMedGoogle Scholar
  10. 10.
    Ito S, Gejyo F. Elevation of serum CA19-9 levels in benign diseases.Intern Med 1999;38:840–1.PubMedGoogle Scholar
  11. 11.
    Ueda T, Shimada E, Urakawa T. The clinicopathologic features of serum CA 19-9-positive colorectal cancers.Surg Today 1994;24:518–25.PubMedCrossRefGoogle Scholar
  12. 12.
    Plebani M, Giacomini A, Beghi L, et al. Serum tumor markers in monitoring patients: interpretation of results using analytical and biological variation.Anticancer Res 1996;16:2249–52.PubMedGoogle Scholar
  13. 13.
    Shimono R, Mori M, Akazawa K, Adachi Y, Sgimachi K. Immunohistochemical expression of carbohydrate antigen 19-9 in colorectal carcinoma.Am J Gastroenterol 1994;89:101–5.PubMedGoogle Scholar
  14. 14.
    Filella X, Molina R, Grau JJ, et al. Prognostic value of CA 19.9 levels in colorectal cancer.Ann Surg 1992;216:55–9.PubMedCrossRefGoogle Scholar
  15. 15.
    Kuusela P, Jalanko H, Roberts P, et al. Comparison of CA 19-9 and carcinoembryonic antigen (CEA) levels in the serum of patients with colorectal diseases.Br J Cancer 1984;49:135–9.PubMedGoogle Scholar
  16. 16.
    Fernandez-Fernandez L, Tejero E, Tieso A. Significance of CA 72-4 in colorectal carcinoma. Comparison with CEA and CA 19-9.Eur J Surg Oncol 1995;21:388–90.PubMedCrossRefGoogle Scholar
  17. 17.
    Duffy MJ. CA 19-9 as a marker for gastrointestinal cancers: a review.Ann Clin Biochem 1998;35:364–70.PubMedGoogle Scholar
  18. 18.
    Morales-Gutierrez C, Vegh I, Colina F, et al. Survival of patients with colorectal carcinoma: possible prognostic value of tissular carbohydrate antigen 19,9 determination.Cancer 1999;86:1675–81.PubMedCrossRefGoogle Scholar
  19. 19.
    Kouri M, Pyrhonen S, Kuusela P. Elevated CA19-9 as the most significant prognostic factor in advanced colorectal carcinoma.J Surg Oncol 1992;49:78–85.PubMedCrossRefGoogle Scholar
  20. 20.
    Lopez JB, Royan GP, Lakhwani MN, Mahadaven M, Timor J. CA 72-4 compared with CEA and CA 19-9 as a marker of some gastrointestinal malignancies.Int J Biol Markers 1999;14:172–7.PubMedGoogle Scholar
  21. 21.
    Nakayama T, Watanabe M, Teramoto T, Kitajima M. Slope analysis of CA19-9 and CEA for predicting recurrence in colorectal cancer patients.Anticancer Res 1997;17:1379–82.PubMedGoogle Scholar
  22. 22.
    Behbehani AI, Al Sayer H, Farghaly M, et al. Prognostic significance of CEA and CA 19-9 in colorectal cancer in Kuwait.Int J Biol Markers 2000;15:51–5.PubMedGoogle Scholar

Copyright information

© The Society of Surgical Oncology, Inc 2002

Authors and Affiliations

  • S. van Ruth
    • 3
  • A. A. M. Hart
    • 1
  • J. M. G. Bonfrer
    • 2
  • V. J. Verwaal
    • 3
  • F. A. N. Zoetmulder
    • 3
  1. 1.Department of RadiotherapyThe Netherlands Cancer Institute/Antoni van Leeuwenhoek HospitalAmsterdamThe Netherlands
  2. 2.Department of Clinical ChemistryThe Netherlands Cancer Institute/Antoni van Leeuwenhoek HospitalAmsterdamThe Netherlands
  3. 3.Department of Surgical OncologyThe Netherlands Cancer Institute/Antoni van Leeuwenhoek HospitalAmsterdamThe Netherlands

Personalised recommendations